...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in rats, studied by microdialysis.
【24h】

Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in rats, studied by microdialysis.

机译:通过微透析研究了扎西他滨(2',3'-二脱氧胞苷)和BEA005(2',3'-二脱氧-3'-羟甲基胞苷)在大鼠血脑屏障中的药代动力学和分布。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Microdialysis was applied to sample the unbound drug concentration in the extracellular fluid in brain and muscle of rats given zalcitabine (2',3'-dideoxycytidine; n = 4) or BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine; n = 4) (50 mg/kg of body weight given subcutaneously). Zalcitabine and BEA005 were analyzed by high-pressure liquid chromatography with UV detection. The maximum concentration of zalcitabine in the dialysate (Cmax) was 31.4 +/- 5. 1 microM (mean +/- standard error of the mean) for the brain and 238. 3 +/- 48.1 microM for muscle. The time to Cmax was found to be from 30 to 45 min for the brain and from 15 to 30 min for muscle. Zalcitabine was eliminated from the brain and muscle with half-lives 1.28 +/- 0.64 and 0.85 +/- 0.13 h, respectively. The ratio of the area under the concentration-time curve (AUC) (from 0 to 180 min) for the brain and the AUC for muscle (AUC ratio) was 0.191 +/- 0.037. The concentrations of BEA005 attained in the brain and muscle were lower than those of zalcitabine, with Cmaxs of 5.7 +/- 1.4 microM in the brain and 61.3 +/- 12.0 microM in the muscle. The peak concentration in the brain was attained 50 to 70 min after injection, and that in muscle was achieved 30 to 50 min after injection. The half-lives of BEA005 in the brain and muscle were 5.51 +/- 1.45 and 0.64 +/- 0.06 h, respectively. The AUC ratio (from 0 to 180 min) between brain and muscle was 0.162 +/- 0.026. The log octanol/water partition coefficients were found to be -1.19 +/- 0.04 and -1.47 +/- 0.01 for zalcitabine and BEA005, respectively. The degrees of plasma protein binding of zalcitabine (11% +/- 4%) and BEA005 (18% +/- 2%) were measured by microdialysis in vitro. The differences between zalcitabine and BEA005 with respect to the AUC ratio (P = 0.481), half-life in muscle (P = 0.279), and level of protein binding (P = 0.174) were not statistically significant. The differences were statistically significant in the case of the half-life in the brain (P = 0.032), clearance (P = 0.046), volume of distribution (P = 0.027) in muscle, and octanol/water partition coefficient (P = 0.019).
机译:微透析用于给大鼠扎西他滨(2',3'-二脱氧胞苷; n = 4)或BEA005(2',3'-二脱氧-3'-羟甲基胞苷;大鼠)脑和肌肉的细胞外液中未结合的药物浓度进行采样。 n = 4)(皮下给予50 mg / kg体重)。扎西他滨和BEA005通过高压液相色谱-紫外检测法进行分析。透析液中扎西他滨的最大浓度(Cmax)为31.4 +/-5。大脑为1 microM(平均值的+/-标准误差),肌肉为238。3+/- 48.1 microM。发现大脑达到Cmax的时间为30至45分钟,肌肉为15至30分钟。扎西他滨的半衰期分别为1.28 +/- 0.64和0.85 +/- 0.13 h。大脑的集中时间曲线(AUC)(0-180分钟)与肌肉的AUC下面积之比(AUC比)为0.191 +/- 0.037。在大脑和肌肉中获得的BEA005浓度低于扎西他滨,在大脑中Cmax为5.7 +/- 1.4 microM,在肌肉中为61.3 +/- 12.0 microM。注射后50至70分钟达到大脑中的峰值浓度,注射后30至50分钟达到肌肉中的峰值浓度。 BEA005在大脑和肌肉中的半衰期分别为5.51 +/- 1.45和0.64 +/- 0.06 h。大脑和肌肉之间的AUC比(从0到180分钟)为0.162 +/- 0.026。对扎西他滨和BEA005,辛醇/水分配系数的对数分别为-1.19 +/- 0.04和-1.47 +/- 0.01。扎西他滨(11%+/- 4%)和BEA005(18%+/- 2%)的血浆蛋白结合度是通过体外微透析测量的。扎西他滨和BEA005之间的AUC比率(P = 0.481),肌肉半衰期(P = 0.279)和蛋白质结合水平(P = 0.174)的差异无统计学意义。在大脑半衰期(P = 0.032),清除率(P = 0.046),肌肉分布体积(P = 0.027)和辛醇/水分配系数(P = 0.019)方面,差异具有统计学意义。 )。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号